Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 10(6) CD34+ cells/kg (1.6-5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 10(6) CD34+ cells/kg (0-24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.
Hübel
K
K
University Hospital of Cologne, Cologne, Germany. kai.huebel@uni-koeln.de
Fresen
M M
MM
Salwender
H
H
Basara
N
N
Beier
R
R
Theurich
S
S
Christopeit
M
M
Bogner
C
C
Galm
O
O
Hartwig
R
R
Heits
F
F
Lordick
F
F
Rösler
W
W
Wehler
D
D
Zander
A R
AR
Albert
M H
MH
Dressler
S
S
Ebinger
M
M
Frickhofen
N
N
Hertenstein
B
B
Kiehl
M
M
Liebler
S
S
von Lilienfeld-Toal
M
M
Weidmann
E
E
Weigelt
C
C
Lange
F
F
Kröger
N
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D001596:Benzylamines; D001781:Blood Component Removal / Q000379:methods; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D057176:Compassionate Use Trials; D000080027:Cyclams; D005260:Female; D005858:Germany; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome; D055815:Young Adult
D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor